KMD-3213 is a selective alpha 1A-adrenoceptor antagonist originally discovered by Kissei Pharmaceutical Co. It was developed by Daiichi Sankyo and Kissei Pharmaceutical and is jointly marketed as Urief in Japan.
KMD-3213 has shown efficacy in significantly improving urinary disturbance soon after dosage and is expected to contribute to improving the quality of life in patients.